Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

CSAI vs ABVX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ABVX Captures Overall Composite Edge (42.4 HOLD vs 38.7 SELL), While CSAI Leads 4–1 on Growth & Valuation Pillars

ABVX Overall Winner 6-Pillar Tally: CSAI 4 – 1 ABVX (1 Tie) Matrix Metrics: CSAI 3 – 5 ABVX

As of Nov 20, 2026, Abivax SA (ABVX) captures the overall head-to-head institutional edge over Cloudastructure, Inc. (CSAI) on higher Unified Composite conviction (42.4/100 HOLD vs. 38.7/100 SELL) after splitting the core matrix 5–3 (led by Options & Positioning), while CSAI wins 4–1 across the 6-pillar growth and valuation breakdown. CSAI trades at $0.48 (N/M Forward P/E, -164.2% operating margin) versus ABVX at $73.20 (N/M Forward P/E, -6270.4% operating margin).

  • Growth vs. Quality Trade-Off: ABVX earns the overall head-to-head edge with a stronger Unified Composite Score (42.4/100 HOLD vs. CSAI 38.7/100 SELL) and 1.55β · 55% Vol risk profile, whereas CSAI leads top-line expansion (+6.1% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: CSAI is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 19.0); meanwhile ABVX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 30.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CSAI vs ABVX
CSAI NASDAQ
Cloudastructure, Inc. Class A Common Stock
Services-Computer Programming, Data Processing, Etc.
$0.48
-24.28% 1D
Market Cap $765,275
TTM Revenue $5.9M
Forward P/E N/M
Beta / 30D Vol 15.27β · 183% Vol
Unified Composite Score
38.7 / 100 SELL
Tech 25.0 Fund 35.0 Flow 50.0 Mom 30.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -36.6%), weak momentum, RSI 19
RSI-14: 19.0 · SMA20: $1.68 · SMA50: $2.34
ABVX NASDAQ Head-to-Head Winner
Abivax SA American Depositary Shares
Pharmaceutical Preparations
$73.20
-9.24% 1D
Market Cap $7.1B
TTM Revenue $4.7M
Forward P/E N/M
Beta / 30D Vol 1.55β · 55% Vol
Unified Composite Score
42.4 / 100 HOLD
Tech 25.0 Fund 38.0 Flow 50.0 Mom 30.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -11.8%), weak momentum, RSI 30
RSI-14: 30.0 · SMA20: $86.08 · SMA50: $91.16

6-Pillar Scorecard Institutional Category Breakdown (CSAI 4 – 1 ABVX)

Columns: Metric · CSAI · ABVX
1. Valuation Multiples CSAI
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 0.1x N/M
2. Growth & Scale CSAI
Revenue Growth (YoY) +6.1% -6.8%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $5.9M $4.7M
Market Cap $765,275 $7.1B
3. Profitability & Quality CSAI
Gross Margin 36.5% 100.0%
Operating Margin -164.2% -6270.4%
Net Profit Margin -166.5% 0.0%
Return on Equity (ROE) -214.8% -252.3%
4. Balance Sheet & Cash Flow CSAI
Cash Generation (TTM) -$9.5M EBITDA -$292M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $2.07 Book/Sh · -214.8% ROE $5.16 Book/Sh · -252.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ABVX
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile N/A (N/A) 76.9% (<1st %ile)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Software - Infrastructure Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CSAI (3) vs ABVX (5)
Institutional Metric CSAI ABVX Criterion Row Edge
Market Capitalization
Scale
$765,275 $7.1B Larger Scale ABVX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+6.1% -6.8% Higher Growth CSAI
Operating Margin (TTM)
Profitability
-164.2% -6270.4% Higher Margin CSAI
Net Profit Margin
Profitability
-166.5% 0.0% Higher Margin ABVX
Return on Equity (ROE)
Capital Efficiency
-214.8% -252.3% Higher ROE CSAI
52-Week Range Position
Momentum
4% ($0–$7) 12% ($63–$149) Stronger Trend ABVX
Beta / 30D Volatility
Risk Regime
15.27β · 183% Vol 1.55β · 55% Vol Lower Realized Risk ABVX
Unified Institutional Score
Composite Signal
38.7 / 100 (SELL) 42.4 / 100 (HOLD) Higher Composite ABVX
Trailing 12M Revenue (USD)
Operating Scale
$5.9M $4.7M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
36.5% 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.1x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$9.5M EBITDA ($2.07 Book/Sh · -214.8% ROE) -$292M EBITDA ($5.16 Book/Sh · -252.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ABVX +59.31 pp
CSAI: -78.18% · ABVX: -18.87%
3M Horizon ABVX +53.7 pp
CSAI: -90.68% · ABVX: -36.98%
6M Horizon CSAI +34.11 pp
CSAI: -5.89% · ABVX: -40.0%
1Y Horizon ABVX +18.31 pp
CSAI: -53.5% · ABVX: -35.19%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CSAI vs ABVX. Trailing 12-month operating profitability (CSAI -164.2% vs ABVX -6270.4%) and valuation multiples (CSAI N/M vs ABVX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CSAI ADR TTM Benchmark FX-Normalized USD
TTM Revenue$5.9M
Gross Margin36.5%
Op. Margin-164.2%
ROE / Fwd P/E-214.8% · N/M
ABVX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$4.7M
Gross Margin100.0%
Op. Margin-6270.4%
ROE / Fwd P/E-252.3% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CSAI BREAKDOWN
71d in phase · OBV DISTRIBUTION
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact CSAI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ABVX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 76.9%
IV Percentile <1st %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ABVX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CSAI Moat Profile Cyclical / Execution-Driven Positioning
Software - Infrastructure Operator
Competes within the Software - Infrastructure value chain with $765,275 market capitalization and -164.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ABVX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $7.1B market capitalization and -6270.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CSAI vs ABVX Key Questions & Quantitative Answers

As of Nov 20, 2026, Abivax SA (ABVX) captures the overall head-to-head institutional edge over Cloudastructure, Inc. (CSAI) on higher Unified Composite conviction (42.4/100 HOLD vs. 38.7/100 SELL) after splitting the core matrix 5–3 (led by Options & Positioning), while CSAI wins 4–1 across the 6-pillar growth and valuation breakdown. CSAI trades at $0.48 (N/M Forward P/E, -164.2% operating margin) versus ABVX at $73.20 (N/M Forward P/E, -6270.4% operating margin). Growth vs. Quality Trade-Off: ABVX earns the overall head-to-head edge with a stronger Unified Composite Score (42.4/100 HOLD vs. CSAI 38.7/100 SELL) and 1.55β · 55% Vol risk profile, whereas CSAI leads top-line expansion (+6.1% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: CSAI is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 19.0); meanwhile ABVX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 30.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CSAI leads the Growth & Scale pillar: CSAI posts +6.1% YoY revenue growth and +0.0% YoY earnings growth on $5.9M TTM revenue (36.5% gross margin, -164.2% operating margin), compared with ABVX at -6.8% YoY revenue growth and +0.0% YoY earnings growth on $4.7M TTM revenue (100.0% gross margin, -6270.4% operating margin). On trailing 12-month operating scale, CSAI generates $5.9M in USD-normalized revenue versus $4.7M for ABVX. In operating R&D and SG&A reinvestment, CSAI deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ABVX.

CSAI screens cheaper on headline valuation multiples. CSAI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.1x EV/Revenue (unreported EBITDA margin), whereas ABVX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CSAI (-214.8% ROE) versus ABVX (-252.3% ROE) capital efficiency.

In options market volatility and institutional positioning, CSAI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (15.27β · 183% Vol realized risk). By comparison, ABVX carries 76.9% implied volatility (<1st %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.55β · 55% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.